|
|
WelcomeWorld Pharma News is an ambitious online news service dedicated to the world pharmaceutical industry. Our main goal is to keep our readers informed about the latest worldwide pharmaceutical news, realizations and achievements.
Register now to be in touch with our last developments and achievements or Subscribe to World Pharma News alerts by Email (a free e-mail delivery powered by Google).
Non progredi est regredi. |
||||
PharmaNews.eu, an advanced web based news project, targeting the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical achievements...For further information, please visit http://www.pharmanews.eu |
|||||
Pharmaceutical Companies[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]Sponsored AdsPharmaceutical RSS NewsStart your day with worldwide pharmaceutical news[ Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda ]  European Commission - Pharmaceuticals US Food and Drug Administration
World Pharma News .net / Published NewsSponsored Ads |
Corporate News Channel
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pfizer Inc announced it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer's biologic portfolio. 
Novo Nordisk has entered a global licence agreement with French biotechnology company C2X Pharma and the French national institute for health and medical research (Inserm) for thrombin-activable factor X. The protein, which is in early preclinical development, is a novel type of bypassing agent, capable of propagating blood clotting independently of factors VIII and IX. 
AstraZeneca announced that it has filed patent infringement actions in United States District Court, District of Delaware, against seven generic drug manufacturers, which have submitted Abbreviated New Drug Applications (ANDAs) for Crestor™. 
GlaxoSmithKline (GSK) and OncoMed Pharmaceuticals (OncoMed) today announced a worldwide strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells which are believed to play a key role in the establishment, metastasis and recurrence of cancer. The alliance with GSK will be conducted through its Center of Excellencefor External Drug Discovery (CEEDD). 
Novartis has expanded its collaboration with the German biotechnology company MorphoSys to create one of the pharmaceutical industry's most comprehensive alliances focused on the discovery and development of antibody-based biologic therapies, the most successful and fastest growing class of biologics. 
In conjunction with World AIDS Day, Earvin "Magic" Johnson, the Magic Johnson Foundation and Abbott (NYSE: ABT) today announced that Cookie Johnson, wife of Earvin "Magic" Johnson will be touring throughout the country in 2008 to educate women on HIV/AIDS. Earvin "Magic" Johnson will continue to be the primary ambassador for the "I Stand With Magic" program to inform people about the disease, encourage people to get tested and if necessary, seek treatment for HIV if they are HIV positive. 
Bristol-Myers Squibb Company (NYSE: BMY) in collaboration with the National AIDS Fund (NAF) launched the fourth annual "Light to Unite" campaign in support of World AIDS Day. Light to Unite shines a light on the ongoing HIV/AIDS epidemic in the U.S. and encourages individuals to get involved in the struggle against the disease through the sharing of knowledge and experiences, and through donations that benefit grassroots HIV/AIDS organizations throughout the country. 
Collexis Holdings, Inc. (OTCBB: CLXS) has acquired its long-time development partner, SyynX Solutions, a privately-held software company based in Cologne, Germany. SyynX Solutions will remain as a subsidiary of Collexis Holdings – with the amendment "a Collexis company", and will take care of existing customers and drive Collexis' business in Europe. 
